New Lung-Box device could save more transplant organs
NCT ID NCT02234128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a device called the Toronto EVLP System that keeps donated lungs warm and breathing outside the body. The goal was to see if it is safe to extend the time doctors can preserve and check the lungs before transplant. 118 adults waiting for a lung transplant took part. Researchers compared their outcomes to standard transplant procedures, focusing on survival and lung function after 30 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Toronto EVLP System (device that keeps donor lungs warm and breathing outside the body)
- What this could lead to
- If successful, this could allow more donor lungs to be used for transplant by giving doctors more time to assess them safely.
- What could go wrong
- This is a safety study, not a test of cure. The device may not improve outcomes, and there are standard risks of lung transplant like organ rejection or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
118 people
The number who actually took part.
- Started
-
Jul 2015
- Finished
-
Nov 2019
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Subject Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Male or female patients * All patients, 18 years of age or older * Patient already on or added to the active waiting list for a single or bilateral lung transplant * Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant * Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant Subject Exclusion Criteria: A subject who meets any of the following criteria will be excluded from participation: * Patients listed for same-side lung re-transplantation * Patients listed for multiple organ transplantation including lung and any other organ * Patients listed for live donor lobar transplant * Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia * Patients not initially consented into the study prior to the time of lung transplant * Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS). Donor Lung Inclusion Criteria for EVLP Assessment: The donor lung must meet at least one of the following criteria to proceed with EVLP: * At the time of the clinical evaluation, the donor PaO2/FiO2 \< 300 mmHg * Donor received ≥ 10 units of blood transfusions * Donation after Cardiac Death (DCD) donor * Expected cold ischemic time \> 6 hours * Donor age ≥ 55 years old * Study Center Investigator requires additional assessment ex vivo and/or extended preservation time Donor Lung Exclusion Criteria for EVLP Assessment: The donor lung is excluded from EVLP if at least one of the following criteria have been met: * The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy * Non-persistent purulent secretions that do not clear by hour 3 on EVLP * The donor lung has confirmed evidence of aspiration * The donor lung has significant mechanical lung injury or trauma * The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility \> 10 hours EVLP Lung Inclusion Criteria for Transplantation: The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator: * PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period * and \< 15% increase from baseline value (defined as the first hour collection point) to final value of pulmonary vascular resistance (PVR) * and \< 15% increase from baseline value to final value of peak airway pressure (PawP) * and \< 15% decrease from baseline value to final value of static lung compliance (Cstat) * and the total preservation time (TPT) does not exceed the following: * the initial CIT-1 time from donor to EVLP \> 1 hour and ≤ 10 hours * the EVLP time \> 3 hours and ≤ 6 hours * the second CIT-2 from EVLP cool down to beginning of recipient implantation must be \> 1 hour and ≤ 6 hours for the first lung * the second CIT-2 from EVLP cool down to beginning of recipient implantation must be \> 1 hour and ≤ 10 hours for the second lung * and Study Center Investigator deems lung function suitable for intended subject EVLP Lung Exclusion Criteria for Transplantation: The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met: * PvO2/FiO2 \< 350 mmHg at final EVLP evaluation time period * or ≥ 15% increase from baseline value to final value of pulmonary vascular resistance (PVR) * or ≥ 15% increase from baseline value to final value of peak airway pressure (PawP) * or ≥ 15% decrease from baseline value to final value of static lung compliance (Cstat) * or TPT exceeds any of the following conditions: * CIT-1 \< 1 hour or \> 10 hours * EVLP \< 3 hours or \> 6 hours * CIT-2 \< 1 hour or \> 6 hours for first lung or \> 10 hours for second lung * or Study Center investigator deems lung function unsuitable for intended subject
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Duke University Health System
Durham, North Carolina, 27705, United States
-
Inova Fairfax Medical Campus
Falls Church, Virginia, 22042, United States
-
Loyola University Medical Center
Chicago, Illinois, 60153, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a stroll beat a sprint for oxygen testing?
- New lung cancer drug shows promise in early trial
- TB's hidden toll on teens: new study probes lasting lung damage
- Scientists hunt for protein clues to Pneumonia's hidden causes
- Can a quick ultrasound spot lung problems? new study aims to find out
- Scientists dive deep into the roots of a mysterious lung disease